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A B S T R A C T
Silver nanoparticles (AgNP) are widely used in a variety of consumable products as antibacterial to prevent
or treat infection. Unfortunately, evidence exits that AgNP induces inflammation which can worsen with re-
peated human exposure. However, there is little or no research on how to mitigate these adverse effects due
to AgNP induced-toxicity. Here, we investigated if surface modification of AgNP by liposomal encapsulation
suppresses AgNP-mediated inflammatory responses in THP1 monocytes and THP1 differentiated macrophages
(TDM). AgNP was encapsulated in a dipalmitoyl phosphatidyl choline- (DPPC)/cholesterol-based liposome by
extrusion through a 100-nm polycarbonate membrane to form Lipo-AgNP. It was found as expected that AgNP
induced significant release of IL-1β, IL-6, IL-8 and TNF-α in THP1 monocytes more than the basal level. Interest-
ingly, release of these cytokines was suppressed by Lipo-AgNP. In TDMs, AgNP and Lipo-AgNP induced IL-8 re-
lease (p<.0001), but Lipo-AgNP maintained IL-8 release at levels significantly lower than that of AgNP (p<.01).
However, both AgNP and Lipo-AgNP suppressed IL-1β and TNF-α release in LPS-stimulated THP1 monocytes and
LPS-stimulated or unstimulated TDM respectively. We finally showed that Lipo-AgNP inhibits STAT-3 and this
may be responsible for regulating the uncontrolled inflammation induced by AgNP likely mediated STAT-3 pro-
tein expression in LPS stimulated THP1 monocytes and TDMs, both LPS-stimulated and unstimulated. This data
showed that Lipo-AgNP suppressed AgNP induced inflammation, making Lipo-AgNP particularly useful in treat-
ment of bacteria induced inflammatory diseases and inflammatory cancers.
1. Introduction
Silver nanoparticles (AgNP) are widely used as an antibacterial agent
and are the active agent in>24% of global nanotechnology driven
commercialised product, in dermal applications, medical apparels and
in sterilisation products for medical equipment (Vance et al., 2015).
While the application of AgNP as an antibacterial agent hold promise
in the treatment of bacterial infection, their increased commercialisa-
tion translates to increased and repeated human exposure. There are re-
ports of skin irritation and permanent discolouration of the eyes and
skin as a result of exposure to AgNP (León-Silva et al., 2016). In sup-
port of this, several in vitro and in vivo studies in recent decades have
demonstrated AgNP-induced inflammatory responses. A repeated-dose
toxicity assessment carried out on mice that were orally administered
with AgNP showed that the nanoparticle, irrespective of size induced
significant expression of IL-1, IL-6 and TNF-α, among other pro-inflam-
matory cytokines in a dose dependent manner (Park et al., 2010).
In primary rat brain micro-vessel endothelial cells (rBMEC), Trick-
ler et al. (2010) demonstrated that AgNP induced secretion of in-
terleukin 1β (IL-1β), IL-2 and tumour necrosis-α (TNF-α). Murphy
et al. (2016) also reported that exposure of THP1 and primary hu-
man monocytes to AgNP resulted in increased mRNA expression of IL-1,
IL-6 and TNF-α. In addition to this, increased inflammasome activation
was suspected due to increased secretion of pro-IL-1β that was observed
upon THP1 exposure to AgNP.
Inflammation is central to the development and progression of vari-
ous chronic diseases including cancer, sepsis, cardiovascular disease, au-
toimmune, and neurodegenerative diseases (David et al., 2016; Jones
et al., 2003; Mukherjee et al., 2016; Pianta et al., 2017; Seol
et al., 2017). Findings in the past decades have shown that IL-1β,
IL-6 and TNF-α are the major pro-inflammatory cytokines with roles
central to promotion and maintenance of systemic inflammation (Her-
nandez-Rodriguez et al., 2004; Mori et al., 2011), making AgNP
exposure a potential hazard. Cytokines are produced by immune cells
such as monocytes and macrophages; and stromal cells such as en-
dothelial cells and fibroblasts for intercellular communication in medi-
ating processes like proliferation, differentiation, growth and immune
cell activation (Landskron et al., 2014). The maintenance of the del-
icate balance between anti- and pro-inflammatory cytokines, however,
is what defines the line between normal condition and disease state
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for different chronic diseases. For example, IL-1β, IL-6 and TNF-α are
the main cytokines driving the damaging inflammatory responses in
rheumatoid arthritis (RA), likely through the perturbation of the bal-
ance between anti- and pro-inflammatory cytokines in RA joints (Mori
et al., 2011). This perturbation may arise due to the amplification of
inflammatory response through the activities of IL-1β, IL-6 and TNF-α in
inducing expression of other pro-inflammatory cytokines through acti-
vation of transcriptional factors such as nuclear factor- κβ (NF-κβ), Sig-
nal Transducer and Activator of Transcription-1 (STAT-1) and STAT-3
(Chung et al., 2017; Pugazhenthi et al., 2013).
Taken together, repeated human exposure to AgNP may result in
chronic inflammation that may favour autoimmunity or cancer devel-
opment and the wide application of AgNP increases risk of AgNP in-
duced adverse effects. In this study, we encapsulated AgNP within a di-
palmitoyl phosphatidylcholine (DPPC)-based liposome to suppress the
nanoparticle-induced inflammation, based on previous studies that have
shown that DPPC suppresses AgNP induced inflammation (Murphy et
al., 2015; Sweeney et al., 2016). We then showed that the liposomal
encapsulation of AgNP suppresses AgNP induced inflammation in both
THP1 monocytes and THP1 cells differentiated into macrophages and
the exposure to liposomal AgNP correlates with inhibition of STAT-3 ex-
pression.
2. Experimental
2.1. Materials and reagents
Silver nitrate (AgNO3) (CAS Number: 7761-88-8), sodium borohy-
dride (NaBH4) (CAS Number: 16940-66-2), dipalmitoyl phosphatidyl
choline (DPPC) (CAS Number: 63-89-8), cholesterol (CAS Number:
57-88-5), Phorbol 12-myristate 13-acetate (PMA) (CAS Number:
16561-29-8) and IL-1β converting enzyme (ICE) inhibitor,
Ac-YVAD-CMK, (Cat Number: 178603-78-6), lipopolysaccharide (LPS)
from E. coli 0111:B4 (Cat Number: LPS25), polymyxin B (CAS Num-
ber: 1405-20-5) were all purchased from Sigma Aldrich, Dublin Ireland.
Chloroform (CAS Number: 67-66-3) was from Fischer Scientific Dublin,
Ireland and Alamar blue (Cat Number: DAL1025) were all from Ther-
moFischer Scientific, Dublin Ireland. Human IL-1β ELISA kit (Cat Num-
ber: HUFI00164), Human TNF-α ELISA kits (Cat Number: HUFI00262)
and Human IL-6 ELISA kit (Cat Number: HUFI00180) were all purchased
from ELISAGenie, Dublin Ireland. Human IL-8 ELISA MAX™ Deluxe (Cat
Number: 431504) was from Biolegend, London, UK.
2.2. AgNP synthesis and encapsulation
AgNP of 21nm size was synthesised through chemical reduction of
silver nitrate (AgNO3) by sodium borohydride (NaBH4) and the resulting
AgNP was encapsulated in dipalmitoyl-phosphatidyl choline (DPPC) and
cholesterol lipid layer to form Lipo-AgNP of 140nm size as described
in our previous study (Yusuf et al., 2018). Briefly, 30mL of 2mM
solution of NaBH4 was added to an Erlenmeyer flask placed in an ice
bath and stirred at 350rpm for 30min to equilibrate after which 6mL of
1mM AgNO3 was added to the NaBH4 solution one drop per second un-
der constant stirring. The stirring was stopped after all the AgNO3 had
been added, and the flask was taken out of the ice bath. To further pre-
vent agglomeration of the AgNP the solution was placed back on the stir-
rer and stirred until room temperature (RT) was achieved. The resulting
golden yellow solution was stable at 4 °C.
For encapsulation, DPPC and cholesterol were dissolved in 5mL
chloroform and the solution was mixed until clear. It was then dried
in a vacuum oven at 52 °C overnight (above melting temperature of
DPPC). The resultant lipid cake was rehydrated in distilled deionised
water (ddH2O) at 60 °C in a shaker. After the lipid was rehydrated,
the AgNP solution was added to make a final lipid concentration of
1mg/mL of DPPC and 0.23mg/mL of cholesterol to give a 7:3M
ratio (Briuglia et al., 2015). The solution was then placed in the
shaker at 60 °C for another 20min after which it was vortexed briefly
and extruded through a 100nm Nanosizer polycarbonate membrane ex-
truder (TTScientific, Knoxville, USA). The resulting colloidal mixture
was stored at 4 °C before use.
2.3. Scanning electron micrograph (SEM) and scanning transmission
electron micrograph (STEM) analysis
SEM micrographs for free and encapsulated AgNP were obtained us-
ing a Hitachi SU-6600 field emission SEM (Hitachi, Maidenhead, UK) at
an accelerating voltage of 25kV and working distance of 8mm. For SEM
analysis, a 5μL drop-cast of each sample was made onto a 5×5mm
pure silicon wafer substrate (Ted Pella Inc., Redding California, USA)
24h prior to obtaining the micrographs and allowed to air dry. For
STEM analysis, 3μL of each sample was drop-cast onto a carbon form-
var copper grid (Agar Scientific Ltd., Stanstead, UK) 24h prior obtaining
and allowed to air dry.
2.4. Dynamic light scattering (DLS) analysis and zeta potential analysis
To measure the hydrodynamic diameter of the nanoparticle in so-
lution, the DLS analysis of both AgNP and Lipo-AgNP was carried out
with Malvern Zetasizer Nano ZS (Malvern Panalytical, Malvern, UK).
The zeta potential measurement of the nanoparticles was also measured
with Malvern Zetasizer Nano ZS instrument set at 25 °C for all the sam-
ples. Nanoparticles were loaded into a pre-rinsed folded capillary cell up
to the marked portion (usually filled with 1ml of sample). An applied
voltage of 15 and 50V was used for Lipo-AgNP and uncoated AgNP re-
spectively and a minimum of three different measurements were made
for each sample.
2.5. Cell culture and THP1 differentiation into monocytic THP1 and THP1
differentiated macrophages
THP1 (ATCC®: TIB-202™) cells were used in this study and were
cultured in RPMI-1640 media supplemented with 2mMl-glutamine and
10% FBS. The cells were incubated at 37 °C, 95% humidity and 5% CO2.
For nanoparticle exposure, cells were seeded in a 24-well plate (VWR,
Dublin, Ireland) at a density of 3×105 cells/ml of culture media and
1.5ml of culture media per well. The cells were stimulated with 100ng/
ml (162nM) PMA for either 24h or 72h to induce differentiation into
matured monocytic THP1 or THP1 differentiated macrophages (TDM)
respectively. The PMA containing media was then replaced with fresh
RPMI media and the cells left to incubate for another 24h (Chanput et
al., 2014).
2.6. Cell exposure
After this, the culture media containing PMA was removed from the
now adhered monocytic THP1 cells or TDMs and another fresh RPMI
media containing 30μg/mL of polymyxin B was replaced for 1h to in-
hibit any LPS that might be present in any reagent used. Polymyxin B
is known to inhibit LPS induced inflammatory response and the concen-
tration used here was found to inhibit up to 10μg/mL LPS contamina-
tion (Xiao-Xiao et al., 2017). After incubation with polymyxin B, the
cells were then treated with different concentrations of uncoated AgNP
and Lipo-AgNP containing an equivalent concentration of the uncoated
AgNP. As a positive control for inflammatory response, cells primed
with 10μg/mL LPS from E. coli 0111:B4 were incorporated on the plate
while a negative control of unexposed cells were both incorporated onto
the plate. The cells were incubated with treatment for specified period
and were stimulated with 5mM ATP for 1h prior to collection of the
supernatant. In some instances, cells exposed to 20μM of Ac-YVAD-
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CMK, a caspase-1 inhibitor (ICEinh), were also incorporated onto the
plate. A minimum of three independent experiments were conducted
and for each independent experiment, four replicate wells were em-
ployed per concentration per plate.
2.7. Cytokine release by sandwiched enzyme linked immunosorbent assay
(ELISA)
For cytokine release assay, RPMI culture media from THP1 promono-
cytes, monocytic THP1 and TDMs exposed to AgNP or Lipo-AgNP post
priming with LPS and ATP challenge were collected at different time
points after which IL-1β, IL-6, IL-8 and TNF-α levels in the culture su-
pernatant were carried out by sandwich ELISA following manufacturer's
instructions. Absorbance was measured at 450nm.
2.8. Cell lysate collection
To collect cell lysate for protein expression analysis, culture media
was aspirated from the cells after which the cells were rinsed in ice cold
1×PBS while the plate was kept on ice. The cells were lysed with 100μl
of RIPA buffer containing protease inhibitor cocktail per 3.5×105 cells
and the cells were scrapped off and pipetted up and down gently to
break up intact cell membranes. The lysate was transferred into a 1.5ml
Eppendorf tube and centrifuged at 13,000× g for 10 mins at 4 °C. The
supernatant was transferred into another 1.5ml Eppendorf tube and
kept on ice to be analysed by ELISA as soon as possible or stored at
−80 °C until analysis.
2.9. Cell viability
Cell viability of nanoparticle exposed cells (both monocytic THP1
and TDM) to the nanoparticles by Alamar Blue assay (AB), a pre-warmed
solution of AB (10% v/v) in serum free media was prepared. The expo-
sure media were removed, and the cells were rinsed with prewarmed
sterile 1×phosphate buffer saline (PBS) after which 1.5ml of AB solu-
tion was added onto the cells. The plates were incubated at 37 °C for 2h
and the resulting florescence of the converted AB dye was measured at
540nm excitation and 595nm emission and wavelengths in a Spectra-
Max® M2 Multi-Mode Microplate Reader.
2.10. Statistical analysis
Statistical analysis of acquired data was carried out with GraphPad
Prism version 7. Data was analysed by Two-way analysis of variance
(ANOVA) with Sidak or Turkey multiple comparisons test to detect sig-
nificance in differences. Statistically significant differences in tests were
indicated for p value<.05.
3. Results
3.1. Characterisation of nanoparticles
Detail of the nanoparticle characterisation and toxicity profile for
AgNP and Lipo-AgNP as well as the drug release profile of Lipo-AgNP
in aqueous environment at physiological pH of 7 and acidic pH of 6.5
is present in our recent publication (Yusuf and Casey, 2019). In sum-
mary, the DLS analysis of the nanoparticles used in this study are de-
picted in Table 1 below. DLS analysis indicated that the hydrodynamic
radius of AgNP was 20.47nm while that of the Lipo-AgNP was found to
be 139.0nm. Zeta potential measurements also showed that the encap-
sulated AgNP (Lipo-AgNP) to be more stable (Zeta of −30.8mV) than
the uncoated AgNP (−25.7mV). The SEM of both AgNP and Lipo-AgNP
confirmed a spherical morphology while the STEM depicted the encap-
sulation of the AgNP within the liposomes shown as grey area in the mi-
crograph (Fig. 1).
Table 1
DLS analysis of both AgNP and Lipo-AgNP.
AgNP Lipo-AgNP
Size (nm) 20.47±7.384 139.0±22.47
PDI 0.186 0.127
Zeta (mV) −25.7 −30.8
3.2. Inflammatory response in monocytic THP1 exposed to AgNP and Lipo-
AgNP
IL-1β plays a central role in inflammatory responses throughs its in-
volvement in regulating its own release in addition to that of IL-6 and its
crosstalk with TNF-α during inflammation (Di Paolo et al., 2015; Mori
et al., 2011). As such, we investigated if exposure of the monocytic
THP1 and TDMs to AgNP or Lipo-AgNP would provoke an inflamma-
tory response in these cell types by evaluating the release of IL-1β, IL-6,
IL-8 and TNF-α upon exposure to the nanoparticles. Prior to nanopar-
ticle exposure or LPS priming, the cells were exposed to polymyxin B
for 1h to inhibit any LPS contamination that may have occurred in pro-
cedures prior to this stage. After this, LPS-primed and unprimed mono-
cytic THP1 and TDMs were exposed to 1μg/ml and 2μg/ml of AgNP or
Lipo-AgNP for 3h after which the cells were stimulated with 5mM ATP
for another 1h when supernatant from the cells was collected for ELISA
analysis of IL-1β release. From Fig. 2A, analysis of IL-1β measurement
in monocytic THP1 indicated that both 1μg/ml and 2μg/ml of AgNP
significantly induced IL-1β release compared to untreated and unprimed
monocytic THP1 (p<.05 and 0.0001 respectively). While Lipo-AgNP
maintained no significant induction of IL-1β compared to the unprimed
and untreated monocytic THP1 at both 1μg/ml and 2μg/ml, Lipo-AgNP
significantly suppressed AgNP induced IL-1β release at both concentra-
tions (p<.05 and 0.0001 respectively). At 1μg/ml concentration, both
AgNP and Lipo-AgNP were able to significantly suppress LPS induced
IL-1β release (p<.05) but at 2μg/ml, the nanoparticles showed no ef-
fect on LPS induction of IL-1β release.
Given that IL-1β and TNF-α interact during inflammation to upregu-
late transcription and expression of pro-inflammatory cytokines, release
of TNF-α upon monocytic THP1 exposure to both AgNP and Lipo-AgNP
was also investigated following the same procedure used for measuring
IL-1β levels. As observed for IL-1β release, Fig. 2B shows that exposure
of unprimed monocytic THP1 to 1μg/ml AgNP resulted in significant
induction of TNF-α compared to untreated and unprimed monocytic
THP1 (p<.05). Coupled with this, exposure of the monocytes to 1μg/
ml Lipo-AgNP did not induce any rise in TNF-α release compared to the
untreated and unprimed monocytic THP1. This coupled with the obser-
vation that both 1μg/ml and 2μg/ml Lipo-AgNP maintained IL-1β levels
similar to that of untreated and unprimed indicates that Lipo-AgNP me-
diate suppression of AgNP-mediated IL-1β and TNF-α release. At 2μg/
ml concentration, both AgNP and Lipo-AgNP induced similar levels of
TNF-α as that in untreated and unprimed control monocytes. The con-
trary was observed for LPS primed monocytic THP1 as exposure to AgNP
but not Lipo-AgNP at 1μg/ml and 2μg/ml resulted in suppression of LPS
mediated induction of TNF-α (p<.01 and p<.0001 respectively). Also,
Lipo-AgNP exposure resulted in significantly higher levels of TNF-α re-
lease compared to AgNP exposed monocytic THP1 at 1μg/ml and 2μg/
ml in the presence of LPS (p<.001).
IL-1β and TNF-α are known regulators of IL-6 release (Palmqvist
et al., 2008) and based on this we next investigated the effect of
AgNP and Lipo-AgNP on IL-6 release. Findings revealed that IL-6 re-
lease was not influenced by LPS priming of monocytic THP1 cells even
in the cells that were exposed to 1μg/ml AgNP and Lipo-AgNP alone or
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Fig. 1. SEM and STEM micrograph of AgNP and Lipo-AgNP: (A) STEM micrograph of AgNP with DLS (inset) (B) SEM of AgNP (C) STEM of Lipo-AgNP with DLS (inset) and (D) STEM of
Lipo-AgNP.
Fig. 2. Lipo-AgNP suppress AgNP mediated secretion of IL-1β, IL-6, IL-8 and TNF-α in monocytic THP1 cells. Monocytic THP1 cells that were either primed with 10μg/mL LPS or unprimed
were exposed to 1μg/ml or 2μg/ml of AgNP and Lipo-AgNP and incubated for 3h. The cells were challenged with 5mM ATP for 1h before culture supernatant was collected for ELISA
analysis of (A) IL-1β (B) TNF-α (C) IL-6 and (D) IL-8 release. Data was presented as mean±SD of 3 independent experiments. Statistically significant differences within same exposure
group were analysed by Two-way ANOVA Tukeys multiple comparison test while differences between different exposure groups were analysed by Sidak multiple comparison test. *p<.05,
**p<.01, ***p<.001, **** p<.0001.
with LPS (Fig. 2C). Conversely, exposure of the monocytic THP1 to
2μg/ml AgNP alone or with LPS priming, induced highly significant
increase in IL-6 release in comparison to untreated unprimed THP1
monocytes (p<.0001 and p<.001 respectively). An interesting finding
here was the suppression of AgNP induced IL-6 release by Lipo-AgNP
both at 1μg/ml and 2μg/ml monocytes (p<.0001 and p<.01 re-
spectively).
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It is noteworthy that LPS priming of monocytic THP1 resulted in sup-
pression of IL-6 release although not significantly (p=.5875). In the
same manner, exposure of LPS-primed monocytic THP1 to 2μg/ml AgNP
resulted in significantly lower release of IL-6 when compared to cells ex-
posed to 2μg/ml AgNP alone. Taken together, these findings might be
indicative of an antagonistic role of LPS on release of IL-6 in the mono-
cytes.
IL-8 is a pro-inflammatory cytokine with tumour promoting roles
(Long et al., 2016). IL-8 release upon exposure of unprimed and
LPS-primed monocytic THP1 to either AgNP or Lipo-AgNP was inves-
tigated. As shown in Figure 2D, there was significant induction of
IL-8 release in LPS primed monocytic THP1 (1422.65pg/ml) compared
with unprimed THP1 monocytes (505pg/ml) (p< 0.0001). As observed
for IL-1β, exposure of the THP1 monocytes to 1μg/ml and 2μg/ml
of Lipo-AgNP resulted in similar IL-8 release profile with those that
were untreated and unprimed with LPS (498.36pg/ml and 354.48pg/
ml respectively). Conversely, AgNP at both 1μg/ml and 2μg/ml re-
sulted in significant induction in released IL-8 levels (1191.17pg/ml
and 1371.61pg/ml respectively) (p< 0.0001), while Lipo-AgNP signif-
icantly suppressed AgNP induced IL-8 release (p< 0.0001). However,
both AgNP and Lipo-AgNP exposure did not suppress LPS induced re-
lease of IL-8 at both concentrations evaluated.
3.3. Inflammatory response in TDMs exposed to AgNP and Lipo-AgNP
Following the discovery that Lipo-AgNP was able to suppress AgNP
and LPS mediated cytokine release in the monocytic THP1 cells, we
proceeded to investigate if this was replicated in TDMs upon their
exposure to AgNP and Lipo-AgNP. This was necessary because
monocytes and macrophages are both important components of the in-
nate immune system in processes leading up to inflammation either dur-
ing injury/infection or disease development such as rheumatoid arthritis
(RA) (Ogle et al., 2016; Roberts et al., 2015). As such, release of the
same set of cytokines measured in the monocytic THP1 were examined
in TDMs under the same conditions.
Analysis of IL-1β release upon LPS priming of TDMs indicated a sig-
nificant increase or enhancement of IL-1β release by TDMs (188.43pg/
ml) compared to the untreated and unprimed control TDMs (174.45pg/
ml) (p< 0.05). Exposure of the unprimed TDMs to 1μg/ml of AgNP and
Lipo-AgNP resulted in significant suppression of IL-1β release (28.41pg/
ml and 41.28pg/ml respectively) (p< 0.0001), although AgNP signifi-
cantly suppressed the IL-1β release compared to Lipo-AgNP (p< 0.05).
In a similar manner, 2μg/ml of AgNP and Lipo-AgNP significantly sup-
pressed IL-1β release in unprimed TDMs (23.73pg/ml and 48.59pg/ml
respectively) (p< 0.0001). Unfortunately, both AgNP and Lipo-AgNP
did not suppress LPS mediated release of IL-1β in TDMs (Figure 3A).
The effect of the nanoparticles on TDM response in terms of TNF-α
release was next examined. As shown in Figure 3B, the first observa-
tion was that TNF-α release in TDMs was more than twice that secreted
by monocytic THP1s under all exposure conditions. It was found that
LPS priming of TDM induced significantly high level of TNF-a release
(3458pg/ml) compared to unprimed TDM (593.33pg/ml) (p< 0.0001).
Exposure of the TDM to 1μg/ml and 2μg/ml of Lipo-AgNP resulted in
significant suppression of TNF-α release (399.43pg/ml and 258.33pg/
ml respectively). AgNP exposure on the other hand only resulted in
significant suppression of TNF-α release at 2μg/ml (341.9pg/ml) (p<
0.01). In TDMs that were primed with LPS, exposure to 2μ
Figure 3. Lipo-AgNP suppress AgNP mediated secretion of IL-1β, IL-6 and TNF-α in TDMs. TDMs that were either primed with 10μg/mL LPS or unprimed were exposed to 1μg/ml or
2μg/ml of AgNP and Lipo-AgNP and incubated for 3h. This was followed by 5mM ATP challenge for 1h before culture supernatant was collected for ELISA analysis of (A) IL-1β (B) TNF-α
(C) IL-6 and (D) IL-8 release. Data was presented as mean±SD of 3 independent experiments. Statistically significant differences within same exposure group were analysed by Two-way
ANOVA Tukeys multiple comparison test while differences between different exposure groups were analysed by Sidak multiple comparison test. *p< 0.05, **p< 0.01, ***p< 0.001, ****
p< 0.0001.
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g/ml AgNP and Lipo-AgNP resulted in significant suppression of LPS in-
duced TNF-α release in the TDMs (3270pg/ml and 3068pg/ml respec-
tively) (p< 0.05 and p< 0.0001 respectively). Furthermore, 2μg/ml
Lipo-AgNP significantly mediated suppression of TNF-α release in com-
parison with AgNP at the same concentration.
As observed in monocytic THP1, LPS priming of TDMs induced sig-
nificant release of IL-6 (42.86pg/ml) when compared with the untreated
and unprimed TDMs (0.76pg/ml) (p< 0.0001). In addition, AgNP and
Lipo-AgNP at 1μg/ml and 2μg/ml did not induce further IL-6 release
as the TDMs exposed to the nanoparticles maintained similar IL-6 re-
lease as the control. While 1μg/ml of AgNP and Lipo-AgNP did not
affect LPS induce IL-6 secretion in TDMs, exposure of the LPS-primed
TDM to 2μg/ml AgNP resulted in significantly higher release of IL-6
(54.39pg/ml) compared to 1μg/ml AgNP (42.59pg/ml) (p< 0.05).
The reverse was observed for 2μg/ml Lipo-AgNP exposure which in-
duced significantly lower IL-6 release compared to 1μg/ml Lipo-AgNP
(37.86pg/ml to 49.21pg/ml respectively) (p< 0.005) (Figure 3C).
In TDMs, observed IL-8 release upon exposure to 1μg/ml AgNP and
Lipo-AgNP (1118.51pg/ml and 1033.22pg/ml respectively) was signif-
icantly higher compared to control untreated group (566pg/ml) (p<
0.0001). The same was observed for the nanoparticles at 2μg/ml con-
centration but AgNP induced significantly higher IL-8 release (1273pg/
ml) compared to Lipo-AgNP (1099.57pg/ml) (p< 0.01) (Figure 3D).
LPS priming of the TDMs also resulted in significantly higher release
of IL-8 at both 1μg/ml and 2μg/ml of both AgNP and Lipo-AgNP (p<
0.0001).
3.4. Cell viability of monocytic THP1 and TDMs at 4h post-exposure to
AgNP and Lipo-AgNP
We have shown that Lipo-AgNP exhibit immunosuppressive role,
even AgNP to some extent. To ensure that the suppressed cytokine re-
lease was not due to reduced cell viability or reduction in number of
cells that are able to release the cytokine upon exposure to AgNP and
Lipo-AgNP, a cell viability assay was carried out. Both LPS primed and
unprimed monocytic THP1 and TDMs were exposed to 1μg/ml and
2μg/ml of either AgNP or Lipo-AgNP for 3h after which the cells were
stimulated with 5mM ATP for another 1h, as done for cytokine release.
The cell viability by Alamar blue was then carried out. As shown in Fig-
ure 4A and B, exposure conditions for AgNP and Lipo-AgNP did not af-
fect the cell viability of both monocytic THP1 and TDM at 4h when the
cytokine release was evaluated.
3.5. Expression of STAT-3 in AgNP and Lipo-AgNP exposed monocytic
THP1 and TDMs
Data obtained from this study have shown that AgNP provokes in-
flammation in both monocytic THP1 and TDMs. We proceeded to in-
vestigate the effect of AgNP and Lipo-AgNP exposure on STAT-3 ex-
pression. Monocytic THP1 and TDMs that were either primed with LPS
or unprimed were exposed to 1μg/ml of either of AgNP or Lipo-AgNP
for 24h. The lysate collected was subjected to sandwich ELISA analy-
sis and result obtained showed that exposure of LPS primed mono-
cytic THP1 to AgNP was correlated with significant induction of STAT-3
expression compared to LPS primed and untreated control monocytes
(p< 0.05) (Figure 5A). It was also found that AgNP exposed and
LPS-primed monocytic THP1 cells expressed significantly higher STAT-3
protein expression when compared with Lipo-AgNP exposed cells (p<
0.01). Contrastingly in TDMs, AgNP exposed cells exhibited significant
expression of STAT-3 in both LPS primed and unprimed TDMs when
compared to primed and unprimed untreated controls (p< 0.05 and
p< 0.001) as well as LPS primed and unprimed Lipo-AgNP exposed
TDMs (p< 0.05 and p< 0.001) (Figure 5B). However, Lipo-AgNP
Figure 4. Cell viability of monocytic THP1 and TDMs. (A) monocytic THP1 and (B) TDMs
that were either primed with 10μg/mL LPS or unprimed were also exposed to 1μg/ml and
2μg/ml AgNP and Lipo-AgNP for 3h followed by 5mM ATP challenge for 1h. The cells
were then exposed incubated in 10% Alamar blue containing RPMI media for 2h. Data is
presented as mean±SD.
exposed TDMs had similar STAT-3 protein expression in THP1 mono-
cytes or TDMs in both LPS primed and unprimed cells.
4. Discussion
We have previously shown that Lipo-AgNP at very low dose in-
duced significant caspase 3/7 dependent cell death compared to un-
coated AgNP in THP1 cells in a ROS independent manner (Yusuf et
al., 2018). Here, the immunomodulatory role of Lipo-AgNP was investi-
gated using THP1 monocytes and TDMs as models for human monocyte
and macrophages respectively.
Macrophages unlike monocytes do not readily secrete IL-1β based
on our findings and those from other studies (Carta et al., 2011;
Madej et al., 2017), this may be attributed to the tissue resident
role of macrophages which is less involved promoting inflammation
rather than secretion of chemokine required for recruitment of immune
cells (Madej et al., 2017). This line of evidence supports our find-
ing that TDMs used in this study secrete significantly higher IL-8 than
monocytic THP1. IL-8 is a chemokine that facilitates recruitment of im-
mune cells like neutrophils to site of inflammation and different lines
of evidence now exist for its tumour promoting chemokine activities
(David et al., 2016; Turner et al., 2014). Our finding here indicated
that AgNP also induced higher release of IL-8 compared to Lipo-AgNP,
although both nanoparticles induced release of IL-8 higher than the
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Figure 5. AgNP induced STAT-3 expression in monocytic THP1 and TDMs. (A) Monocytic
THP1 and (B) TDMs that were unprimed or primed with 10μg/mL LPS were also exposed
with either of 1μg/ml AgNP or Lipo-AgNP for 24h. Lysates were collected and analysed by
sandwich ELISA for STAT-3 expression. Statistically significant differences within same ex-
posure group were analysed by Two-way ANOVA Tukeys multiple comparison test while
differences between different exposure groups were analysed by Sidak multiple compari-
son test. *p< 0.05, *** p< 0.001.
basal levels in TDMs. In addition to this, AgNP induction of IL-8 re-
lease in THP1 monocytes was similar to that induced by LPS and this
may indicate a possible contribution of AgNP mediated inflammation
that may favour tumour development. LPS has been demonstrated to in-
duced cancer development and promote tumour invasion and metasta-
sis (Kurago et al., 2008; Seol et al., 2017), which may be linked to
the IL-8 secretion and the chemokine activity. As such, AgNP stimula-
tion of IL-8 release may facilitate IL-8 chemokine activity in the same
manner. This may also explain the hormetic effect of AgNP in stimu-
lating THP1 cell proliferation (Yusuf and Casey, 2019)and in HepG2
and A549 cancer cells (Jiao et al., 2014; Sthijns et al., 2017). In-
terestingly, HepG2 cell proliferation have been shown in another study
to be inhibited by gallic acid through inhibition of IL-8 secretion (Lima
et al., 2016), highlighting the possible contribution of AgNP-induced
IL=8 secretion to cancer cell proliferation. Although, IL-1β release in
the AgNP-exposed TDMs was significantly less than in AgNP-exposed
THP1 monocytes, LPS priming of the TDM alone or with ATP stim-
ulation resulted in IL-1β release comparable to that exhibited by the
monocytic cell even under caspase-1 inhibition indicating no effect of
AgNP or Lipo-AgNP on IL-1β release. Priming of TDMs might have re-
sulted in much more higher transcription rate of NLRP3 in addition to
the alternate AIM2 inflammasome utilised by macrophages (Turner et
al., 2014), resulting in no net effect of caspase-1 inhibition of IL-1β re-
lease upon ATP stimulation.
Inflammation is tightly associated with activities of reactive oxygen
species (ROS). Endogenous ROS level can induce cellular responses that
activate redox sensitive proteins like NF-κβ causing inflammation due
to upregulation of NF-κβ target genes such as IL-1β, IL-6 and TNF-α
(Forrester et al., 2018; Mittal et al., 2014; Wang et al., 2007).
Likewise, inflammatory response can induce generation of ROS from
NADPH oxidase and mitochondrial induced oxidative stress (Yang et
al., 2007). Many studies have documented ROS generation to be AgNP
main mechanism of action as an antibacterial, even as anticancer
(El-Hussein and Hamblin, 2017; Gurunathan et al., 2013; Xu et
al., 2012; Yuan et al., 2017), as such we hypothesised Lipo-AgNP will
suppress AgNP induced inflammation as it does AgNP ROS generation.
In this study, exposure of the THP1 monocytes to AgNP resulted in
significant increase in basal release of IL-1β, IL-6, IL-8 and TNF-α but
only IL-8 in TDMs where suppression of IL-1β and TNF-α release was
also observed in response to AgNP exposure. In support of this, evi-
dence that AgNP induce inflammation is largely present in the litera-
ture. Sweeney et al. (2016) showed that AgNP induced secretion of
IL-6 and IL-8 in mouse neuronal cells human alveolar type-I-like epithe-
lial cells. In the same manner, Murphy et al. (2016) demonstrated in-
creased gene expression of IL-1, IL-6 and TNF-α and increased secretion
of pro-IL-1β upon exposure of THP-1 and primary human blood mono-
cytes to AgNP. These observations have also been recorded in non-hu-
man models. Park et al. (2011) demonstrated that intra-tracheal in-
stillation of silver nanoparticle in mice resulted in a time and dose de-
pendent increase in release of IL-1, IL-2, IL-6 and TNF-α. It was also
found that AgNP resulted in upregulation of genes associated with in-
flammation and tissue damage. Huang et al. (2015) also showed in
mouse nerve cells that AgNP induced increased release of IL-1β as well
as increased gene expression of CXCL13 chemokine and glutathione syn-
thetase likely due to induced oxidative stress. Thus, this observed in-
flammation may be linked to ROS generation by AgNP. Interestingly,
Lipo-AgNP suppressed both AgNP-mediated inflammation and basal cy-
tokine release by significantly suppressing the release of IL-1β, IL-6,
IL-8 and TNF-α in THP1 monocyte. In TDMs, Lipo-AgNP suppressed
IL-1β and TNF-α release while maintaining basal level of IL-6 which
was aggravated by AgNP. Coupled with the finding from our previ-
ous study that Lipo-AgNP suppresses generation of ROS (Yusuf et al.,
2018), DPPC which is the major component of the liposome encap-
sulating AgNP in Lipo-AgNP is known to also possess an immunosup-
pressive feature (Murphy et al., 2015). Sweeney et al. (2016) had
shown that a DPPC containing commercial surfactant prevented release
of IL-6 and IL-8 in addition to the near abolishment of ROS generation
in human alveolar type-I-like epithelial cells. As such, Lipo-AgNP may
have suppressed the inflammatory response by preventing generation
of ROS, supporting our finding that AgNP generated ROS induced the
observed inflammation. The immunosuppressive activity of Lipo-AgNP
opens an application in treatment of RA and other inflammatory dis-
eases. Involvement of bacteria and bacterial-induced inflammation have
been reported in the development of RA due to the microbe exacerba-
tion of inflammation and oxidative stress, and sometimes induced au-
toimmunity (Olsen-Bergem et al., 2016; Pretorius et al., 2017). As
such, Lipo-AgNP can serve as a double-edged sword to suppress the in-
duced inflammation at the joint and to exert its antibacterial effect on
the pathogens within the RA joint.
As a major PAMP responsible for bacterial induced inflammation
during infection, LPS binding to CD14, TLR2 and TLR4 are promi-
nent to initiation of cytokine release. The application of AgNP as an-
tibacterial is fared to drive inflammation into a chronic state that may
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favour development of diseases like cancer and autoimmunity. It was
discovered that AgNP supressed LPS-induced IL-1β (at 1μg/ml) and
TNF-α release (at both concentration) while Lipo-AgNP (at 1μg/ml)
only suppressed release of IL-1β in THP1 monocytes. While AgNP sig-
nificantly enhanced LPS induced-IL-6 release, Lipo-AgNP exposure of
THP1 monocytes did not induce IL-6 release. In TDMs, only 2μg/ml
Lipo-AgNP mediated suppression of LPS-induced TNF-α. The reason for
suppression of LPS induced IL-1β and TNF-α release by either of AgNP
or Lipo-AgNP in monocytic THP1 or TDM is not known but it could
be that LPS interaction with AgNP modifies the surface chemistry of
both AgNP/Lipo-AgNP and LPS resulting in alteration in interaction be-
tween LPS and the TLRs. Thus, subsequently modulating expected in-
flammatory response. However, further studies are required to probe
this possibility. Another possible explanation could be that both AgNP
and Lipo-AgNP at the right concentrations can inhibit iNOS (inducible
nitric oxide synthase) which may have resulted in suppression of LPS-in-
duced IL-1β and TNF-α. In a study by Sarkar et al. (2008), allylpy-
rocatechol obtained from crude extract of from piper beetle leaf was
shown to inhibit iNOS mRNA expression resulting in suppression of
LPS-induced secretion of TNF-α, COX-2 and IL-12p40 in RAW 264.7
macrophages. Other compounds such as neocryptotanshinone and narin-
genin, which are plant extracts were also shown in different studies to
inhibit LPS-induced mRNA and protein expression of IL-1β, IL-6 and
TNF-α in RAW 264.7 macrophages upon inhibition of iNOS (Kumar and
Abraham, 2017; Wu et al., 2015). A study supporting the activity of
AgNP in suppression of LPS induced inflammation through suppression
of iNOS and nitric oxide was that of Haase et al. (2014), who showed
that AgNP suppressed nitric oxide synthesis in human neutrophils and
macrophages. Another study also reported that AgNP attenuated the ex-
pression of iNOS inhibiting production of nitric oxide in Hep-G2 cells
(Zuberek et al., 2017). Although findings of other studies have shown
that AgNP can induce expression of iNOS due to increased ROS genera-
tion such as in pancreatic cancer and osteoblastic cell lines (Barcinska
et al., 2018; Zielinska et al., 2016), this may be as a result of dif-
fering cellular responses to AgNP because of the different genetic back-
grounds.
We have demonstrated that AgNP induced inflammatory responses,
which is suppressed by encapsulation in DPPC based liposome. In par-
ticular, AgNP induced release of IL-1β, IL-6 and TNF-α indicating that
it may induce persistent inflammation through STAT-3. To investigate
this possibility, the effect of AgNP on the expression of STAT-3, a tran-
scriptional factor in the JAK/STAT pathway known to be involved in
sustained inflammatory response through its regulation especially by
IL-6 family of protein (Wang et al., 2013), was examined. It was
found that exposure of LPS-monocytic THP1 to AgNP resulted in sig-
nificant induction of STAT-3 expression. On the other hand, TDMs ex-
posure to AgNP was found to correlate with significant expression of
STAT-3 irrespective of LPS priming. This finding in addition to those
existing in the literature suggests a relationship between AgNP expo-
sure and sustenance of inflammatory response mediated by activating
STAT-3 expression. For example, IL-1β, IL-6 and TNF-α as found to be
induced by AgNP in this study have been previously shown to induce
STAT-3 phosphorylation and activation causing prolonged inflamma-
tion and joint destruction in RA mice (Mori et al., 2011). IL-6 bind-
ing with its receptor, IL-6R, is known to indirectly induce activation
Figure 6. Mechanism of AgNP sustenance of perpetual inflammation. Entry of AgNP into the cell can result in generation of ROS through mitochondrial membrane disruption and cy-
tochrome C release or through ionisation of the nanoparticle by the aqueous milieu of the cytoplasm. The generated ROS could activate IKK which in turns activate NF-κβ facilitating its
translocation into the nucleus to initiate transcription of pro-inflammatory cytokines like IL-1β, IL-6 and TNF-α. Release of IL-6 and its subsequent interaction with IL-6R can then activate
the JAK/STAT-3 pathway leading to phosphorylation and activation of STAT-3 creating a continuous loop of cytokine release.
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of STAT-3 through IL-6R interaction with epidermal growth factor re-
ceptor (EGFR) or activation of Janus kinase (JAK) leading to STAT-3 ac-
tivation (Figure 6). This STAT-3 activation subsequently results in pro-
longed inflammation through continued expression of proteins like the
MAP kinase (MAPK) and interleukin-1 receptor associated kinase bind-
ing protein-1 (IRAK1BP1) that play crucial role in inflammation and
cancer (Wang et al., 2013). The fact that Lipo-AgNP exposure cor-
relates with STAT-3 expression in untreated control THP1 monocytes
and TDMs may be indicative of the suppressive role of the encapsula-
tion on AgNP mediated inflammation. Taken together, Lipo-AgNP may
be a potential in treatment of RA and the pannus formation in RA joint.
Like a double-edged sword, Lipo-AgNP may treat the RA killing the of-
ten-colonised bacteria and suppressing the provoked chronic inflamma-
tion. In addition, Lipo-AgNP may be useful in treating other bacterial
diseases that are characterised with heightened inflammation like ulcer-
ative colitis and Crohn’s disease or even cancer like inflammatory breast
cancer.
5. Conclusion
While AgNP suppression of LPS-induced IL-1β and TNF-α may be in-
dicative of a somewhat favourable contribution of the nanoparticle dur-
ing LPS triggered inflammation, AgNP provocation of inflammatory re-
sponse in the absence of LPS indicates otherwise. AgNP is mainly used
in preventing bacterial infection which means human exposure to AgNP
is highly likely under sterile conditions such as in sterilised items like
garments, cosmetics and medical equipment that contain AgNP with
intent of preventing rather than treating infection. As such, the in-
creased contact in such conditions may likely drive inflammation that
are favourable for chronic diseases like cancer and inflammatory dis-
eases. On the other hand, we have shown that Lipo-AgNP effectively
suppressed AgNP mediated inflammatory responses in both monocytic
THP1 and TDMs. Based on the evidence presented here and that of our
previous study (Yusuf et al., 2018), Lipo-AgNP application will not
only translate to lower AgNP concentration required to achieve effec-
tive cytotoxicity, but will likely mitigate AgNP-mediated inflammation,
preventing vicious cycle of chronic inflammation that favours disease
development and progression. This will prove especially useful in treat-
ing inflammation induced bacterial disease such as RA and the associ-
ated pannus development, ulcerative colitis and Crohn’s disease, all of
which are characterised with bacterial infection and chronic inflamma-
tion since AgNP is an antibacterial coupled with the immunosuppressive
properties of Lipo-AgNP.
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